Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...

The scale of the problem has led analysts to predict that the market for RSV vaccines could eventually be worth several billion dollars a year. In trials, GSK’s vaccine significantly reduced the ...

Last year, the stock declined 62.6%, significantly underperforming the S&P 500 Index’s ($SPX) gain of 25%. Moderna reported ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab ... threshold in its first full year on the market. Supply has been outstripped by demand, and Sanofi ...

Who is the most powerful doctor in the world? Read on to understand why despite not being a doctor, Bill Gates is considered ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (the ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Built around the latest Bosch CX Gen 5 motor, the Santa Cruz Vala delivers one of the most well-rounded riding experiences in ...